- Home
- LXRX
as 03-28-2025 4:00pm EST
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | THE WOODLANDS |
| Market Cap: | 124.4M | IPO Year: | 2000 |
| Target Price: | $3.67 | AVG Volume (30 days): | 29.6M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.28 - $2.45 | Next Earning Date: | 03-06-2025 |
| Revenue: | $31,081,000 | Revenue Growth: | 2481.48% |
| Revenue Growth (this year): | -56.24% | Revenue Growth (next year): | 101.91% |
Latest Lexicon Pharmaceuticals Inc. News
LXRX Breaking Stock News: Dive into LXRX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump
GlobeNewswire
a day ago
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
GlobeNewswire
22 days ago
Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025
GuruFocus.com
22 days ago
Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
Zacks
23 days ago
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Associated Press Finance
23 days ago
Lexicon: Q4 Earnings Snapshot
GlobeNewswire
23 days ago
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
MT Newswires
24 days ago
Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2
Compare LXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LXRX Lexicon Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.